Genetically modified mice related to schizophrenia and other psychoses: Seeking phenotypic insights into the pathobiology and treatment of negative symptoms

European Neuropsychopharmacology

Volumn 24, Issue 5, 2014, Pages 800-821

  O'Tuathaigh, Colm M P ^a,b   Desbonnet, Lieve ^c   Waddington, John L ^b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^c UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Behavioural phenotyping; Candidate gene mutants; Dopamine; Glutamate; Mutant mouse models; Negative symptoms; Schizophrenia; Social behaviour

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; CATECHOL METHYLTRANSFERASE; DISRUPTED IN SCHIZOPHRENIA 1 PROTEIN; DYSBINDIN; GLUTAMIC ACID; IONOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OXYTOCIN; OXYTOCIN RECEPTOR; PHENCYCLIDINE; REELIN;

ANHEDONIA; ARTICLE; COGNITIVE DEFECT; COPY NUMBER VARIATION; ENVIRONMENTAL ENRICHMENT; EXPLORATORY BEHAVIOR; FOOD PREFERENCE; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC RISK; GENETICALLY ENGINEERED MOUSE STRAIN; GENOTYPE ENVIRONMENT INTERACTION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MEMORY; MESENCHYMAL STEM CELL; METHODOLOGY; MOTIVATION; MOUSE; MOUSE MUTANT; NEGATIVE SYNDROME; NEUROPSYCHOLOGICAL TEST; NEUROTRANSMISSION; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REWARD; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; SENSORY GATING; SOCIAL BEHAVIOR; SOCIAL COGNITION; SOCIAL INTERACTION; SOCIAL LEARNING; ANIMAL; DISEASE MODEL; GENETICS; PATHOPHYSIOLOGY; PSYCHOLOGY; PSYCHOSIS; TRANSGENIC MOUSE;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MICE, TRANSGENIC; PHENOTYPE; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84899865150     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2013.08.009     Document Type: Article

References (224)

1. Abazyan B., Nomura J., Kannan G., Ishizuka K., Tamashiro K.L., Nucifora F., Pogorelov V., Ladenheim B., Yang C., Krasnova I.N., Cadet J.L., Pardo C., Mori S., Kamiya A., Vogel M.W., Sawa A., Ross C.A., Pletnikov M.V. Prenatal interaction of mutant DISC1 and immune activation produces adult psychopathology. Biol. Psychiatry 2010, 68:1172-1181.
2. Akbarian S. Restoring GABAergic signaling and neuronal synchrony in schizophrenia. Am. J. Psychiatry 2008, 165:1507-1509.
3. Allen N.C., Bagade S., McQueen M.B., Ioannidis J.P., Kavvoura F.K., Khoury M.J., Tanzi R.E., Bertram L. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat. Genet. 2008, 40:827-834.
4. Arakawa H., Cruz S., Deak T. Attractiveness of illness-associated odorant cues in female rats is modulated by ovarian hormones, but not associated with pro-inflammatory cytokine levels. Brain Behav. Immun. 2012, 26:40-49.
5. Arakawa H., Blanchard D.C., Arakawa K., Dunlap C., Blanchard R.J. Scent marking behavior as an odorant communication in mice. Neurosci. Biobehav. Rev. 2008, 32:1236-1248.
6. Arguello P.A., Gogos J.A. Modeling madness in mice: one piece at a time. Neuron 2006, 52:179-196.
7. Babovic D., O'Tuathaigh C.M., O'Connor A.M., O'Sullivan G.J., Tighe O., Croke D.T., et al. Phenotypic characterization of cognition and social behavior in mice with heterozygous versus homozygous deletion of catechol-O-methyltransferase. Neuroscience 2008, 155:1021-1029.
8. Baird J.P., Turgeon S., Wallman A., Hulick V. Behavioral processes mediating phencyclidine-induced decreases in voluntary sucrose consumption. Pharmacol. Biochem. Behav. 2008, 88:272-279.
9. Balu D.T., Coyle J.T. Neuroplasticity signaling pathways linked to the pathophysiology of schizophrenia. Neurosci. Biobehav. Rev. 2011, 35:848-870.
10. Barch D.M., Dowd E.C. Goal representations and motivational drive in schizophrenia: The role of prefrontal-striatal interactions. Schizophr. Bull. 2010, 36:919-934.
11. Barkataki I., Kumari V., Das M., Hill M., Morris R., O'Connell P., Taylor P., Sharma T. A neuropsychological investigation into violence and mental illness. Schizophr. Res. 2005, 74:1-13.
12. Barkus C., Feyder M., Graybeal C., Wright T., Wiedholz L., Izquierdo A., Kiselycznyk C., Schmitt W., Sanderson D.J., Rawlins J.N., Saksida L.M., Bussey T.J., Sprengel R., Bannerman D., Holmes A. Do GluA1 knockout mice exhibit behavioral abnormalities relevant to the negative or cognitive symptoms of schizophrenia and schizoaffective disorder?. Neuropharmacology 2012, 62:1263-1272.
13. Barros C.S., Calabrese B., Chamero P., Roberts A.J., Korzus E., Lloyd K., Stowers L., Mayford M., Halpain S., Muller U. Impaired maturation of dendritic spines without disorganization of cortical cell layers in mice lacking NRG1/ErbB signaling in the central nervous system. Proc. Natl. Acad. Sci. USA 2009, 106:4507-4512.
14. Barzilay R., Ganz J., Sadan O., Ben-Zur T., Bren Z., Hinden N., Taler M., Lev N., Gil-Ad I., Weizman A., Offen D. Mesenchymal stem cells protect from sub-chronic phencyclidine insult in vivo and counteract changes in astrocyte gene expression in vitro. Eur. Neuropsychopharmacol. 2012, (12):281-287. (doi:pii:S0924-977X).
15. Belforte J.E., Zsiros V., Sklar E.R., Jiang Z., Yu G., Li Y., Quinlan E.M., Nakazawa K. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat. Neurosci. 2010, 13:76-83.
16. Berridge K.C., Robinson T.E., Aldridge J.W. Dissecting components of reward: 'liking', 'wanting', and learning. Curr. Opin. Pharmacol. 2009, 9:65-73.
17. Blanchard JJ., Horan WP., Brown SA. Diagnostic differences in social anhedonia: a longitudinal study of schizophrenia and major depressive disorder. J Abnorm. Psychol. 2001, 110:363-371.
18. Blanchard J.J., Cohen A.S. The structure of negative symptoms within schizophrenia: 953 implications for assessment. Schizophr. Bull. 2006, 32:238-245.
19. Bora E., Yucel M., Pantelis C. Theory of mind impairment in schizophrenia: meta-analysis. Schizophr. Res. 2009, 109:1-9.
20. Brzózka M.M., Radyushkin K., Wichert S.P., Ehrenreich H., Rossner M.J. Cognitive and sensorimotor gating impairments in transgenic mice overexpressing the schizophrenia susceptibility gene Tcf4 in the brain. Biol. Psychiatry 2010, 68:33-40.
21. Cagniard B., Balsam P.D., Brunner D., Zhuang X.X. Mice with chronically elevated dopamine exhibit enhanced motivation, but not learning, for a food reward. Neuropsychopharmacology 2006, 31:1362-1370.
22. Carlson G.C. Glutamate receptor dysfunction and drug targets across models of autism spectrum disorders. Pharmacol. Biochem. Behav. 2012, 100:850-854.
23. Chadman K.K., Yang M., Crawley J.N. Criteria for validating mouse models of psychiatric diseases. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 2009, 150B:1-11.
24. Chen Y.J., Johnson M.A., Lieberman M.D., Goodchild R.E., Schobel S., Lewandowski N., Rosoklija G., Liu R.C., Gingrich J.A., Small S., Moore H., Dwork A.J., Talmage D.A., Role L.W. Type III neuregulin-1 is required for normal sensorimotor gating, memory-related behaviors, and corticostriatal circuit components. J. Neurosci. 2008, 28:6872-6883.
25. Cinque C., Pondiki S., Oddi D., Di Certo M.G., Marinelli S., Troisi A., Moles A., D'Amato F.R. Modeling socially anhedonic syndromes: genetic and pharmacological manipulation of opioid neurotransmission in mice. Transl. Psychiatry 2012, 2:e155.
26. Clifton N.E., Morisot N., Girardon S., Millan M.J., Loiseau F. Enhancement of social novelty discrimination by positive allosteric modulators at metabotropic glutamate 5 receptors: adolescent administration prevents adult-onset deficits induced by neonatal treatment with phencyclidine. Psychopharmacology 2013, 225:579-594.
27. Clapcote S.J., Lipina T.V., Millar J.K., Mackie S., Christie S., Ogawa F., Lerch J.P., Trimble K., Uchiyama M., Sakuraba Y., Kaneda H., Shiroishi T., Houslay M.D., Henkelman R.M., Sled J.G., Gondo Y., Porteous D.J., Roder J.C. Behavioral phenotypes of Disc1 missense mutations in mice. Neuron 2007, 54:387-402.
28. Cornblatt B.A., Lencz T., Smith C.W., Correll C.U., Auther A.M., Nakayama E. The schizophrenia prodrome revisited: a neurodevelopmental perspective. Schizophr. Bull. 2003, 29:633-651.
29. Coyle J.T. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell. Mol. Neurobiol. 2006, 26:365-384.
30. Coyle J.T., Tsai G. The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology 2004, 174:32-38.
31. Crusio W.E., Goldowitz D., Holmes A., Wolfer D. Standards for the publication of mouse mutant studies. Genes Brain Behav. 2009, 8:1-4.
32. Deacon R.M. Assessing nest building in mice. Nat. Protoc. 2006, 1:1117-1119.
33. Debbané M, Glaser B, David MK, Feinstein C, Eliez S. Psychotic symptoms in children and adolescents with 22q11.2 deletion syndrome: Neuropsychological and behavioral implications. Schizophr. Res. 2006, 84:187-193.
34. Depoortere R., Dargazanli G., Estenne-Bouhtou G., Coste A., Lanneau C., Desvignes C., Poncelet M., Heaulme M., Santucci V., Decobert M., Cudennec A., Voltz C., Boulay D., Terranova J.P., Stemmelin J., Roger P., Marabout B., Sevrin M., Vige X., Biton B., Steinberg R., Francon D., Alonso R., Avenet P., Oury-Donat F., Perrault G., Griebel G., George P., Soubrie P., Scatton B. Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Neuropsychopharmacology 2005, 30:1963-1985.
35. Der-Avakian A., Markou A. The neurobiology of anhedonia and other reward-related deficits. Trends Neurosci. 2012, 35:68-77.
36. Desbonnet L., Waddington J.L., Tuathaigh C.M. Mice mutant for genes associated with schizophrenia: common phenotype or distinct endophenotypes?. Behav. Brain Res. 2009, 204:258-273.
37. Desbonnet L., O'Tuathaigh C., Clarke G., O'Leary C., Petit E., Clarke N., Tighe O., Lai D., Harvey R., Cryan J.F., Dinan T.G., Waddington J.L. Phenotypic effects of repeated psychosocial stress during adolescence in mice mutant for the schizophrenia risk gene neuregulin-1: a putative model of genexenvironment interaction. Brain Behav. Immun. 2012, 26:660-671.
38. Desbonnet L., O'Tuathaigh C.M., Waddington J.L. Modeling schizophrenia: uncovering novel therapeutic targets. Expert. Rev. Clin. Pharmacol. 2012, 5:667-676.
39. Doherty J.L., O'Donovan M.C., Owen M.J. Recent genomic advances in schizophrenia. Clin. Genet. 2012, 81:103-109.
40. Drew M.R., Simpson E.H., Kellendonk C., Herzberg W.G., Lipatova O., Fairhurst S., Kandel E.R., Malapani C., Balsam P.D. Transient overexpression of striatal D2 receptors impairs operant motivation and interval timing. J. Neurosci. 2007, 27:7731-7739.
41. Duffy L., Cappas E., Lai D., Boucher A.A., Karl T. Cognition in transmembrane domain neuregulin 1 mutant mice. Neuroscience 2010, 170:800-807.
42. Duncan G.E., Moy S.S., Perez A., Eddy D.M., Zinzow W.M., Lieberman J.A. Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function. Behav. Brain Res. 2004, 153:507-519.
43. Ehrlichman R.S., Luminais S.N., White S.L., Rudnick N.D., Ma N., Dow H.C., Kreibich A.S., Abel T., Brodkin E.S., Hahn C.G., Siegel S.J. Neuregulin 1 transgenic mice display reduced mismatch negativity, contextual fear conditioning and social interactions. Brain Res 2009, 1294:116-127.
44. Etherton M.R., Blaiss C.A., Powell C.M., Südhof T.C. Mouse neurexin-1alpha deletion causes correlated electrophysiological and behavioral changes consistent with cognitive impairments. Proc. Natl. Acad. Sci. USA 2009, 106:17998-18003. 10.1073/pnas.0910297106.
45. Falls D.L. Neuregulins: functions, forms, and signaling strategies. Exp. Cell Res. 2003, 284:14-30.
46. Feifel D., Macdonald K., Nguyen A., Cobb P., Warlan H., Galangue B., Minassian A., Becker O., Cooper J., Perry W., Lefebvre M., Gonzales J., Hadley A. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol. Psychiatry 2010, 68:678-680.
47. Feng Y.Q., Zhou Z.Y., He X., Wang H., Guo X.L., Hao C.J., Guo Y., Zhen X.C., Li W. Dysbindin deficiency in sandy mice causes reduction of snapin and displays behaviors related to schizophrenia. Schizophr. Res. 2008, 106:218-228.
48. Fernandes C., Paya-Cano J.L., Sluyter F., D'Souza U., Plomin R., Schalkwyk L.C. Hippocampal gene expression profiling across eight mouse inbred strains: towards understanding the molecular basis for behaviour. Eur. J. Neurosci. 2004, 19:2576-2582.
49. File S.E., Seth P. A review of 25 years of the social interaction test. Eur. J. Pharmacol. 2003, 463:35-53.
50. Fisahn A, Neddens J, Yan L, Buonanno A. Neuregulin-1 modulates hippocampal gamma oscillations: implications for schizophrenia. Cereb. Cortex 2009, 19:612-618.
51. Foussias G., Remington G. Negative symptoms in schizophrenia: avolition and Occam's razor. Schizophr. Bull. 2010, 36:359-369.
52. Fuchs H., Gailus-Durner V., Adler T., Aguilar-Pimentel J.A., Becker L., Calzada-Wack J., Da Silva-Buttkus P., Neff F., Götz A., Hans W., Hölter S.M., Horsch M., Kastenmüller G., Kemter E., Lengger C., Maier H., Matloka M., Möller G., Naton B., Prehn C., Puk O., Rácz I., Rathkolb B., Römisch-Margl W., Rozman J., Wang-Sattler R., Schrewe A., Stöger C., Tost M., Adamski J., Aigner B., Beckers J., Behrendt H., Busch D.H., Esposito I., Graw J., Illig T., Ivandic B., Klingenspor M., Klopstock T., Kremmer E., Mempel M., Neschen S., Ollert M., Schulz H., Suhre K., Wolf E., Wurst W., Zimmer A., Hrabě de Angelis M. Mouse phenotyping. Methods 2011, 53:120-123.
53. Gai X., Xie H.M., Perin J.C., Takahashi N., Murphy K., Wenocur A.S., D'arcy M., O'Hara R.J., Goldmuntz E., Grice D.E., Shaikh T.H., Hakonarson H., Buxbaum J.D., Elia J., White P.S. Rare structural variation of synapse and neurotransmission genes in autism. Mol. Psychiatry 2012, 17:402-411.
54. Gandal M.J., Sisti J., Klook K., Ortinski P.I., Leitman V., Liang Y., Thieu T., Anderson R., Pierce R.C., Jonak G., Gur R.E., Carlson G., Siegel S.J. GABAB-mediated rescue of altered excitatory-inhibitory balance, gamma synchrony and behavioral deficits following constitutive NMDAR-hypofunction. Transl. Psychiatry 2012, 2:e142.
55. Gard D.E., Kring A.M., Gard M.G., Horan W.P., Green M.F. Anhedonia in schizophrenia: distinctions between anticipatory and consummatory pleasure. Schizophr. Res. 2007, 93:253-260.
56. Gauthier J., Siddiqui T.J., Huashan P., Yokomaku D., Hamdan F.F., Champagne N., Lapointe M., Spiegelman D., Noreau A., Lafrenière R.G., Fathalli F., Joober R., Krebs M.O., DeLisi L.E., Mottron L., Fombonne E., Michaud J.L., Drapeau P., Carbonetto S., Craig A.M., Rouleau G.A. Truncating mutations in NRXN2 and NRXN1 in autism spectrum disorders and schizophrenia. Hum. Genet. 2011, 130:563-573.
57. Gogos J.A., Morgan M., Luine V., Santha M., Ogawa S., Pfaff D., Karayiorgou M. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behaviour. Proc. Natl. Acad. Sci. USA 1998, 95:9991-9996.
58. Gold J.M., Waltz J.A., Prentice K.J., Morris S.E., Heerey E.A. Reward processing in schizophrenia: a deficit in the representation of value. Schizophr. Bull. 2008, 34:835-847.
59. Gold J.M., Strauss G.P., Waltz J.A., Robinson B.M., Brown J.K., Frank M.J. Negative symptoms of schizophrenia are associated with abnormal effort-cost computations. Biol. Psychiatry 2013, (13):35-38. (2013 Feb 7. doi:pii: S0006-3223).
60. Green M.F., Horan W.P. Social cognition in scihzophrenia. Curr. Direct. Psychol. Sci. 2010, 19:243e8.
61. Green M.F., Hellemann G., Horan W.P., Lee J., Wynn J.K. From perception to functional outcome in schizophrenia: modeling the role of ability and motivation. Arch. Gen. Psychiatry 2012, 69(12):1216-1224.
62. Gu Z., Jiang Q., Fu A.K., Ip N.Y., Yan Z. Regulation of NMDA receptors by neuregulin signaling in prefrontal cortex. J. Neurosci. 2005, 25:4974-4984.
63. Guillin O., Abi-Dargham A., Laruelle M. Neurobiology of dopamine in schizophrenia. Int. Rev. Neurobiol. 2007, 78:1-39.
64. Guilloux J.P., Seney M., Edgar N., Sibille E. Integrated behavioral z-scoring increases the sensitivity and reliability of behavioral phenotyping in mice: relevance to emotionality and sex. J. Neurosci. Methods 2011, 197:21-31.
65. Gur R.E., Calkins M.E., Gur R.C., Horan W.P., Nuechterlein K.H., Seidman L.J., Stone W.S. The consortium on the genetics of schizophrenia: neurocognitive endophenotypes. Schizophr. Bull. 2007, 33:49-68.
66. Guo X., Hamilton P.J., Reish N.J., Sweatt J.D., Miller C.A., Rumbaugh G. Reduced expression of the NMDA receptor-interacting protein SynGAP causes behavioural abnormalities that model symptoms of schizophrenia. Neuropsychopharmacology 2013, (in press).
67. Hahn C.G., Wang H.Y., Cho D.S., Talbot K., Gur R.E., Berrettini W.H., Bakshi K., Kamins J., Borgmann-Winter K.E., Siegel S.J., Gallop R.J., Arnold S.E. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat. Med. 2006, 12:824-828.
68. Halene T.B., Ehrlichman R.S., Liang Y., Christian E.P., Jonak G.J., Gur T.L., Blendy J.A., Dow H.C., Brodkin E.S., Schneider F., Gur R.C., Siegel S.J. Assesssment of NMDA receptor NR1 subunit hypofunction in mice as a model for schizophrenia. Genes Brain Behav. 2009, 8:661-675.
69. Han L., Picker J.D., Schaevitz L.R., Tsai G., Feng J., Jiang Z., et al. Phenotypic characterization of mice heterozygous for a null mutation of glutamate carboxypeptidase II. Synapse 2009, 63:625-635.
70. Han S., Tai C., Westenbroek R.E., Yu F.H., Cheah C.S., Potter G.B., Rubenstein J.L., Scheuer T., de la Iglesia H.O., Catterall W.A. Autistic-like behaviour in Scn1a+/- mice and rescue by enhanced GABA-mediated neurotransmission. Nature 2012, 489:385-390.
71. Hattori S., Murotani T., Matsuzaki S., Ishizuka T., Kumamoto N., Takeda M., Tohyama M., Yamatodani A., Kunugi H., Hashimoto R. Behavioral abnormalities and dopamine reductions in sdy mutant mice with a deletion in Dtnbp1, a susceptibility gene for schizophrenia. Biochem. Biophys. Res. Commun. 2008, 373:298-302.
72. Haque F.N., Lipina T.V., Roder J.C., Wong A.H. Social defeat interacts with Disc1 mutations in the mouse to affect behavior. Behav. Brain Res. 2012, 233:337-344.
73. Hashimoto R., Straub R.E., Weickert C.S., Hyde T.M., Kleinman J.E., Weinberger D.R. Expression analysis of neuregulin-1 in the dorsolateral prefrontal cortex in schizophrenia. Mol. Psychiatry 2004, 9:299-307.
74. Harper K.M., Hiramoto T., Tanigaki K., Kang G., Suzuki G., Trimble W., Hiroi N. Alterations of social interaction through genetic and environmental manipulation of the 22q11.2 gene Sept5 in the mouse brain. Hum. Mol. Genet. 2012, 21:3489-3499.
75. Harrison P.J., Law A.J. Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol. Psychiatry 2006, 60:132-140.
76. Harrison P.J., Law A.J., Eastwood S.L. Glutamate receptors and transporters in the hippocampus in schizophrenia. Ann. N. Y. Acad. Sci. 2003, 1003:94-101.
77. Hennah W., Thomson P., McQuillin A., Bass N., Loukola A., Anjorin A., Blackwood D., Curtis D., Deary I.J., Harris S.E., Isometsa E.T., Lawrence J., Lonnqvist J., Muir W., Palotie A., Partonen T., Paunio T., Pylkko E., Robinson M., Soronen P., Suominen K., Suvisaari J., Thirumalai S., Clair D., Gurling H., Peltonen L., Porteous D. DISC1 association, heterogeneity and interplay in schizophrenia and bipolar disorder. Mol. Psychiatry 2009, 14:865-873.
78. Hikida T., Jaaro-Peled H., Seshadri S., Oishi K., Hookway C., Kong S., et al. Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans. Proc. Natl. Acad. Sci. USA 2007, 104:14501-14506.
79. Hiramoto T., Kang G., Suzuki G., Satoh Y., Kucherlapati R., Watanabe Y., Hiroi N. Tbx1: identification of a 22q11.2 gene as a risk factor for autism spectrum disorder in a mouse model. Hum. Mol. Genet. 2011, 20:4775-4785.
80. Inta D., Vogt M.A., Perreau-Lenz S., Schneider M., Pfeiffer N., Wojcik S.M., Spanagel R., Gass P. Sensorimotor gating, working and social memory deficits in mice with reduced expression of the vesicular glutamate transporter VGLUT1. Behav. Brain Res. 2012, 228:328-332.
81. Javitt D.C. Glycine transport inhibitors in the treatment of schizophrenia. Handb. Exp. Pharmacol. 2012, 213:367-399.
82. Javitt D.C., Zukin S.R., Heresco-Levy U., Umbricht D. Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. Schizophr Bull. 2012, 38:958-966.
83. Jeon D., Shin H.S. A mouse model for observatiobservationalonal fear learning and the empathetic response. Curr. Protoc. Neurosci. 2011, 57:8.27.1-8.27.9.
84. Jones C.A., Watson D.J., Fone K.C. Animal models of schizophrenia. Br. J. Pharmacol. 2011, 164:1162-1194.
85. Karlsson R.M., Tanaka K., Saksida L.M., Bussey T.J., Heilig M., Holmes A. Assessment of glutamate transporter GLAST (EAAT1)-deficient mice for phenotypes relevant to the negative and executive/cognitive symptoms of schizophrenia. Neuropsychopharmacology 2009, 34:1578-1589.
86. Kato T., Kasai A., Mizuno M., Fengyi L., Shintani N., Maeda S., Yokoyama M., Ozaki M., Nawa H. Phenotypic characterization of transgenic mice overexpressing neuregulin-1. PLoS One 2010, 5:e14185.
87. Keefe R.S., Bilder R.M., Davis S.M., Harvey P.D., Palmer B.W., Gold J.M., Meltzer H.Y., Green M.F., Capuano G., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Davis C.E., Hsiao J.K., Lieberman J.A. CATIE Investigators; Neurocognitive Working Group. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch. Gen. Psychiatry 2007, 64:633-647.
88. Kegeles L.S., Abi-Dargham A., Zea-Ponce Y., Rodenhiser-Hill J., Mann J.J., Van Heertum R.L., Cooper T.B., Carlsson A., Laruelle M. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol. Psychiatry 2000, 48:627-640.
89. Kellendonk C., Simpson E.H., Polan H.J., Malleret G., Vronskaya S., Winiger V., Moore H., Kandel E.R. Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron 2006, 49:603e615.
90. Keshavan M.S., Tandon R., Boutros N.N., Nasrallah H.A. Schizophrenia, "just the facts": what we know in 2008 Part 3: neurobiology. Schizophr. Res. 2008, 106:89-107.
91. Keshavan M.S., Nasrallah H.A., Tandon R. Schizophrenia, "Just the Facts" 6. Moving ahead with the schizophrenia concept: from the elephant to the mouse. Schizophr. Res. 2011, 127:3-13.
92. Kiley-Brabeck K., Sobin C. Social skills and executive function deficits in children with the 22q11 deletion syndrome. Appl. Neuropsychol. 2006, 13:258-268.
93. Kirkpatrick B., Strauss G.P., Nguyen L., Fischer B.A., Daniel D.G., Cienfuegos A., Marder S.R. The brief negative symptom scale: psychometric properties. Schizophr. Bull. 2011, 37:300-305.
94. Kirby B.P., Waddington J.L., O'Tuathaigh C.M. Advancing a functional genomics for schizophrenia: psychopathological and cognitive phenotypes in mutants with gene disruption. Brain Res. Bull. 2010, 83:162-176.
95. Kohler C.G., Walker J.B., Martin E.A., Healey K.M., Moberg P.J. Facial emotion perception in schizophrenia: a meta-analytic review. Schizophr. Bull. 2010, 36:1009-1019.
96. Kuroda K., Yamada S., Tanaka M., Iizuka M., Yano H., Mori D., Tsuboi D., Nishioka T., Namba T., Iizuka Y., Kubota S., Nagai T., Ibi D., Wang R., Enomoto A., Isotani-Sakakibara M., Asai N., Kimura K., Kiyonari H., Abe T., Mizoguchi A., Sokabe M., Takahashi M., Yamada K., Kaibuchi K. Behavioral alterations associated with targeted disruption of exons 2 and 3 of the Disc1 gene in the mouse. Hum. Mol. Genet. 2011, 20:4666-4683.
97. Kurtz M.M., Moberg P.J., Ragland J.D., Gur R.C., Gur R.E. Symptoms vs.neurocognitive test performance as predictors of psychosocial status in schizophrenia: a 1- and 4-year prospective study. Schizophr. Bull. 2005, 31:167-174.
98. Kurtz M.M., Olfson R.H., Rose J. Self-efficacy and functional status in schizophrenia: relationship to insight, cognition and negative symptoms. Schizophr. Res. 2013, 145:69-74.
99. Labrie V., Lipina T., Roder J.C. Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia. Psychopharmacology 2008, 200:217-230.
100. Labrie V., Wang W., Barger S.W., Baker G.B., Roder J.C. Genetic loss of d-amino acid oxidase activity reverses schizophrenia-like phenotypes in mice. Genes Brain Behav. 2010, 9:11-25.
101. Lacaria M., Spencer C., Gu W., Paylor R., Lupski J.R. Enriched rearing improves behavioral responses of an animal model for CNV-based autistic-like traits. Hum. Mol. Genet. 2012, 21:3083-3096.
102. Law A.J., Kleinman J.E., Weinberger D.R., Weickert C.S. Disease-associated intronic variants in the ErbB4 gene are related to altered ErbB4 splice-variant expression in the brain in schizophrenia. Hum. Mol. Genet. 2007, 16:129-141.
103. Li B., Woo R.-S., Mei L., Malinow R. The neuregulin-1 receptor ErbB4 controls glutamatergic synapse maturation and plasticity. Neuron 2007, 54:583-597.
104. Li M., Budin R., Fleming A.S., Kapur S. Effects of novel antipsychotics, amisulpiride and aripiprazole, on maternal behavior in rats. Psychopharmacology (Berl) 2005, 181:600-610.
105. Li W., Zhou Y., Jentsch J.D., Brown R.A.M., Tian X., Ehninger D. Specific developmental disruption of disrupted-in-schizophrenia-1 function results in schizophrenia-related phenotypes in mice. Proc. Natl. Acad. Sci. USA 2007, 104:18280-18285.
106. Lin C.H., Huang C.L., Chang Y.C., Chen P.W., Lin C.Y., Tsai G.E., Lane H.Y. Clinical symptoms, mainly negative symptoms, mediate the influence of neurocognition and social cognition on functional outcome of schizophrenia. Schizophr. Res. 2013, 146:231-237.
107. Lincoln T.M., Mehl S., Kesting M.L., Rief W. Negative symptoms and social cognition: identifying targets for psychological interventions. Schizophr. Bull. 2011, 37:S23-S32.
108. Lipska B.K., Weinberger D.R. To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 2000, 23:223-239.
109. Liu W., Pappas G.D., Carter C.S. Oxytocin receptors in brain cortical regions are reduced in haploinsufficient (+/-) reeler mice. Neurol. Res. 2005, 27:339-345.
110. Logge W., Kingham J., Karl T. Behavioural consequences of IVC cages on male and female C57BL/6J mice. Neuroscience 2013, 237:285-293.
111. Low N.C., Hardy J. What is a schizophrenic mouse?. Neuron 2007, 54:348-349.
112. Ma T.M., Abazyan S., Abazyan B., Nomura J., Yang C., Seshadri S., Sawa A., Snyder S.H., Pletnikov M.V. Pathogenic disruption of DISC1-serine racemase binding elicits schizophrenia-like behavior via D-serine depletion. Mol. Psychiatry. 2013, 18:557-567.
113. Malaspina D., Coleman E. Olfaction and social drive in schizophrenia. Arch. Gen. Psychiatry. 2003, 60:578-584.
114. Malla A.K., Takhar J.J., Norman R.M., Manchanda R., Cortese L., Haricharan R., Verdi M., Ahmed R. Negative symptoms in first episode non-affective psychosis. Acta Psychiatr. Scand. 2002, 105:431-439.
115. Mancuso F., Horan W.P., Kern R.S., Green M.F. Social cognition in psychosis: multidimensional structure, clinical correlates, and relationship with functional outcome. Schizophr. Res. 2011, 125:143-151.
116. Markram K, Markram H. The intense world theory-a unifying theory of the neurobiology of autism. Front. Hum. Neurosci. 2010, 4:224.
117. Mead A.N., Stephens D.N. Selective disruption of stimulus-reward learning in glutamate receptor gria1 knock-out mice. J. Neurosci. 2003, 23:1041-1048.
118. Mead A.N., Brown G., Le Merrer J., Stephens D.N. Effects of deletion of gria1 or gria2 genes encoding glutamatergic AMPA-receptor subunits on place preference conditioning in mice. Psychopharmacology (Berl) 2005, 179:164-171.
119. Mei L., Xiong W.C. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat. Rev. Neurosci. 2008, 9:437-452.
120. Millan M.J., Agid Y., Brune M., Bullmore E.T., Carter C.S., Clayton N.S., Connor R., Davis S., Deakin B., DeRubeis R.J., Dubois B., Geyer M.A., Goodwin G.M., Gorwood P., Jay T.M., Joels M., manusy I.M., Meyer-Lindenberg A., Murphy D., Rolls E., Saletu B., Spedding M., Sweeney J., Whittington M., Young L.J. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat. Rev. Drug Discov. 2012, 11:141-168.
121. Miyakawa T., Leiter L.M., Gerber D.J., Gainetdinov R.R., Sotnikova T.D., Zeng H., Caron M.G., Tonegawa S. Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. Proc. Natl. Acad. Sci. USA 2003, 100:8987-8992.
122. Möhler H, Boison D, Singer P, Feldon J, Pauly-Evers M, Yee BK. Glycine transporter 1 as a potential therapeutic target for schizophrenia-related symptoms: evidence from genetically modified mouse models and pharmacological inhibition. Biochem. Pharmacol. 2011, 81:1065-1077.
123. Mohn A.R., Gainetdinov RR, Caron MG, Koller BH. Mice with reduced NMDA receptor expression display behaviours related to schizophrenia. Cell 1999, 98:427-436.
124. Montag C., Brockmann E.M., Lehmann A., Müller D.J., Rujescu D., Gallinat J. Association between oxytocin receptor gene polymorphisms and self-rated 'empathic concern' in schizophrenia. PLoS One 2012, 7:e51882.
125. Moore S., Kelleher E., Corvin A. The shock of the new: progress in schizophrenia genomics. Curr. Genomics 2011, 12:517-524.
126. Moy S.S., Nadler J.J., Perez A., Barbaro R.P., Johns J.M., Magnuson T.R., Piven J., Crawley J.N. Sociability and preference for social novelty in five inbred strains: an approach to assess autistic-like behavior in mice. Genes Brain Behav. 2004, 3:287-302.
127. Moy S.S., Troy Ghashghaei H., Nonneman R.J., Weimer J.M., Yokota Y., Lee D., Lai C., Threadgill D.W., Anton E.S. Deficient NRG1-ERBB signaling alters social approach: relevance to genetic mouse models of schizophrenia. J. Neurodev. Disord. 2009, 1:302-312.
128. Mullen B.R., Khialeeva E., Hoffman D.B., Ghiani C.A., Carpenter E.M. Decreased reelin expression and organophosphate pesticide exposure alters mouse behaviour and brain morphology. ASN Neuro 2012, 5:1.
129. Murphy B.P., Chung Y.C., Park T.W., McGorry P.D. Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr. Res. 2006, 88:5-25.
130. Nadler J.J., Moy S.S., Dold G., Trang D., Simmons N., Perez A., Young N.B., Barbaro R.P., Piven J., Magnuson T.R., Crawley J.N. Automated apparatus for quantitation of social approach behaviors in mice. Genes Brain Behav. 2004, 3:303-314.
131. Nagai T., Ibi D., Yamada K. Animal model for schizophrenia that reflects gene-environment interactions. Biol. Pharm. Bull. 2011, 34:1364-1368.
132. Nestler E.J., Hyman S.E. Animal models of neuropsychiatric disorders. Nat. Neurosci. 2010, 13:1161-1169.
133. Neve K.A. The Dopamine Receptors 2010, Humana Press, New York.
134. O'Donovan M.C., Craddock N.J., Owen M.J. Genetics of psychosis; insights from views across the genome. Hum. Genet. 2009, 126:3-12.
135. O'Leary, C., Desbonnet, L., O'Tuathaigh, C., Tighe, O., Clarke, N., Petit, E., Lai, D., Harvey, R., Waddington, J.L., 2012. Combined Effects of Prenatal vs. Postnatal Environmental Manipulations on Behaviour and Immune-Related Gene Expression in Mice with Transmembrane Deletion of the Schizophrenia Risk Gene Neuregulin-1. Program No. 224.05. 2012 Neuroscience Meeting Planner. Society for Neuroscience, New Orleans, LA (online).
136. O'Tuathaigh C.M., Babovic D., O'Meara G., Clifford J.J., Croke D.T., Waddington J.L. Susceptibility genes for schizophrenia: characterisation of mutant mouse models at the level of phenotypic behaviour. Neurosci. Biobehav. Rev. 2007, 31:60-78.
137. O'Tuathaigh C.M., Babovic D., O'Sullivan G.J., Clifford J.J., Tighe O., Croke D.T., Harvey R., Waddington J.L. Phenotypic characterization of spatial cognition and social behavior in mice with 'knockout' of the schizophrenia risk gene neuregulin 1. Neuroscience 2007, 147:18-27.
138. O'Tuathaigh C.M., O'Connor A.M., O'Sullivan G.J., Lai D., Harvey R., Croke D.T., Waddington J.L. Disruption to social dyadic interactions but not emotional/anxiety-related behaviour in mice with heterozygous 'knockout' of the schizophrenia risk gene neuregulin-1. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:462-466.
139. O'Tuathaigh C.M., Hryniewiecka M., Behan A., Tighe O., Coughlan C., Desbonnet L., Cannon M., Karayiorgou M., Gogos J.A., Cotter D.R., Waddington J.L. Chronic adolescent exposure to Delta-9- tetrahydrocannabinol in COMT mutant mice: impact on psychosis-related and other phenotypes. Neuropsychopharmacology 2010, 35:2262-2273.
140. O'Tuathaigh C.M., Kirby B.P., Moran P.M., Waddington J.L. Mutant mouse models: genotype-phenotype relationships to negative symptoms in schizophrenia. Schizophr. Bull. 2010, 36:271-288.
141. O'Tuathaigh, C.M., Desbonnet, L., Perez-Branguli, F., Petit, E., O'Leary, C., Clarke, N., Tighe, O., Harvey, R., Mitchell, K., Waddington, J., 2012. Mice with Simultaneous Disruption of DISC1 and NRG1 Genes Exhibit Phenotypes Related to Schizophrenia. Program No. 663.19. 2012 Neuroscience Meeting Planner. Society for Neuroscience, New Orleans, LA (online).
142. Ognibene E., Adriani W., Laviola G. Neurobehavioural disorders in the infant reeler mouse model: interaction of genetic vulnerability and consequences of maternal separation. Behav. Brain Res. 2007, 177:142-149.
143. Olszewski R.T., Wegorzewska M.M., Monteiro A.C., Krolikowski K.A., Zhou J., Kozikowski A.P., Long K., Mastropaolo J., Deutsch S.I., Neale J.H. Phencyclidine and dizocilpine induced behaviours reduced by N-acetylaspartylglutamate peptidase inhibition viametabotropic glutamate receptors. Biol. Psychiatry 2008, 63:86-91.
144. Papaleo F., Weinberger D.R. Dysbindin and schizophrenia: it's dopamine and glutamate all over again. Biol. Psychiatry 2011, 69:2-4.
145. Parmentier-Batteur S., Hutson P.H., Menzel K., Uslaner J.M., Mattson B.A., O'Brien J.A., Magliaro B.C., Forest T., Stump C.A., Tynebor R.M., Anthony N.J., Tucker T.J., Zhang X.F., Gomez R., Huszar S.L., Lambeng N., Fauré H., Le Poul E., Poli S., Rosahl T.W., Rocher J.P., Hargreaves R., Williams T.M. Mechanism based neurotoxicity of mGlu5 positive allosteric modulators - Development challenges for a promising novel antipsychotic target. Neuropharmacology 2013, (12):596-605. (doi:pii: S0028-3908).
146. Patterson T.L., Moscona S., McKibbin C.L., Davidson K., Jeste D.V. Social skills performance assessment among older patients with schizophrenia. Schizophr. Res. 2001, 48:351-360.
147. Pearson B.L., Bettis J.K., Meyza K.Z., Yamamoto L.Y., Blanchard D.C., Blanchard R.J. Absence of social conditioned place preference in BTBR T+tf/J mice: relevance for social motivation testing in rodent models of autism. Behav. Brain Res. 2012, 233:99-104.
148. Penn D.L., Sanna L.J., Roberts D.L. Social cognition in schizophrenia: an overview. Schizophr. Bull. 2008, 34:408-411.
149. Perona M.T.G., Waters S., Hall F.S., Sora I., Lesch K.P., Murphy D.L., Caron M., Uhl G.R. Animal models of depression in dopamine,serotonin, and norepinephrine transporter knockout mice: prominent effects of dopamine transporter deletions. Behav. Pharmacol. 2008, 19:566-574.
150. Petit E., O'Tuathaigh C., Kirby B., Desbonnet L., Niahm C., Tighe O., O'Leary C., Joel J., Shaw A., Sheardown S., Morrison A.D., Wilson S., Shapland E. Phenotypic studies on a novel mutant with targeted deletion of the schizophrenia risk gene Dtnbp1 (dysbindin). FENS 2012, 550. (page number, 124.12).
151. Pilowsky L.S., Bressan R.A., Stone J.M., Erlandsson K., Mulligan R.S., Krystal J.H., Ell P.J. First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol. Psychiatry 2006, 11:118-119.
152. Piskulic D., Addington J., Cadenhead K.S., Cannon T.D., Cornblatt B.A., Heinssen R., Perkins D.O., Seidman L.J., Tsuang M.T., Walker E.F., Woods S.W., McGlashan T.H. Negative symptoms in individuals at clinical high risk of psychosis. Psychiatry Res. 2012, 196:220-224.
153. Pletnikov M.V., Ayhan Y., Nikolskaia O., Xu Y., Ovanesov M.V., Huang H. Inducible expression of mutant human DISC1 in mice is associated with brain and behavioural abnormalities reminiscent of schizophrenia. Mol Psychiatry 2008, 13:173-186.
154. Pobbe R.L., Pearson B.L., Defensor E.B., Bolivar V.J., Young W.S., Lee H.J., Blanchard D.C., Blanchard R.J. Oxytocin receptor knockout mice display deficits in the expression of autism-related behaviors. Horm. Behav. 2012, 61:436-444.
155. Podhorna J., Didriksen M. The heterozygous reeler mouse: behavioural phenotype. Behav. Brain Res. 2004, 153:43-54.
156. Porteous D.J., Millar J.K., Brandon N.J., Sawa A. DISC1 at 10: connecting psychiatric genetics and neuroscience. Trends Mol. Med. 2011, 17:699-706.
157. Powell C.M., Miyakawa T. Schizophrenia-relevant behavioural testing in rodent models: a uniquely human disorder?. Biol. Psychiatry 2006, 59:1198-1207.
158. Pratt J., Winchester C., Dawson N., Morris B. Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap. Nat. Rev. Drug Discov. 2012, 11:560-579.
159. Purcell S.M., International Schizophrenia Consortium, Wray N.R., Stone J.L., Visscher P.M., O'Donovan M.C., Sullivan P.F., Sklar P. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009, 460:748-752.
160. Rabinowitz J., Levine S.Z., Garibaldi G., Bugarski-Kirola D., Berardo C.G., Kapur S. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr. Res. 2012, 137:147-150.
161. Ramocki M.B., Zoghbi H.Y. Failure of neuronal homeostasis results in common neuropsychiatric phenotypes. Nature 2008, 455:912-918.
162. Richardson N.R., Roberts D.C. Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy. J. Neurosci. Methods 1996, 66:1-11.
163. Rodriguiz R.M., Chu R., Caron M.G., Wetsel W.C. Aberrant responses in social interaction of dopamine transporter knockout mice. Behav. Brain Res. 2004, 148:185-198.
164. Salamone J.D., Steinpreis R.E., McCullough L.D., Smith P., Grebel D., Mahan K. Haloperidol and nucleus accumbens dopamine depletion suppress lever pressing for food but increase free food consumption in a novel food choice procedure. Psychopharmacology 1991, 104:515-521.
165. Sams-Dodd F. Distinct effects of d-amphetamine and phencyclidine on the social behaviour of rats. Behav. Pharmacol. 1995, 6:55-65.
166. Sams-Dodd F. Effects of dopamine agonists and antagonists on PCP-induced stereotyped behaviour and social isolation in the rat social interaction test. Psychopharmacology 1998, 135:182-193.
167. Sams-Dodd F. Phencyclidine in the social interaction test: an animal model of schizophrenia with face and predictive validity. Rev. Neurosci. 1999, 10:59-90.
168. Saunders J.A., Tatard-Leitman V.M., Suh J., Billingslea E.N., Roberts T.P., Siegel S.J. Knockout of NMDA receptors in parvalbumin interneurons recreates autism-like phenotypes. Autism Res. 2013, 6:69-77.
169. Scattoni M.L., Crawley J., Ricceri L. Ultrasonic vocalizations: a tool for behavioural phenotyping of mouse models of neurodevelopmental disorders. Neurosci. Biobehav. Rev. 2009, 33:508-515.
170. Schaevitz L.R., Picker J.D., Rana J., Kolodny N.H., Shane B., Berger-Sweeney J.E., Coyle J.T. Glutamate carboxypeptidase II and folate deficiencies result in reciprocal protection against cognitive and social deficits in mice: implications for neurodevelopmental disorders. Dev. Neurobiol. 2012, 72:891-905.
171. Shamir A., Kwon O.B., Karavanova I., Vullhorst D., Leiva-Salcedo E., Janssen M.J., Buonanno A. The importance of the NRG-1/ErbB4 pathway for synaptic plasticity and behaviors associated with psychiatric disorders. J. Neurosci. 2012, 32:2988-2997.
172. Shi J., Levinson D.F., Duan J., Sanders A.R., Zheng Y., Pe'er I., Dudbridge F., Holmans P.A., Whittemore A.S., Mowry B.J., Olincy A., Amin F., Cloninger C.R., Silverman J.M., Buccola N.G., Byerley W.F., Black D.W., Crowe R.R., Oksenberg J.R., Mirel D.B., Kendler K.S., Freedman R., Gejman P.V. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 2009, 460:753-757.
173. Shoji H., Toyama K., Takamiya Y., Wakana S., Gondo Y., Miyakawa T. Comprehensive behavioral analysis of ENU-induced Disc1-Q31L and -L100P mutant mice. BMC Res. Notes 2012, 5:108.
174. Silverman J.L., Yang M., Lord C., Crawley J.N. Behavioural phenotyping assays for mouse models of autism. Nat. Rev. Neurosci. 2010, 11:490-502.
175. Silverman J.L., Smith D.G., Rizzo S.J., Karras M.N., Turner S.M., Tolu S.S., Bryce D.K., Smith D.L., Fonseca K., Ring R.H., Crawley J.N. Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism. Sci. Transl. Med. 2012, 4:131ra51.
176. Simpson E.H., Kellendonk C., Ward R.D., Richards V., Lipatova O., Fairhurst S., Kandel E.R., Balsam P.D. Pharmacologic rescue of motivational deficit in an animal model of the negative symptoms of schizophrenia. Biol. Psychiatry 2011, 69:928-935.
177. Smith K.S., Berridge K.C. Opioid limbic circuit for reward: interaction between hedonic hotspots of nucleus accumbens and ventral pallidum. J. Neurosci. 2007, 27:1594-1605.
178. Snyder M.A., Gao W.J. NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia. Front. Cell. Neurosci. 2013, 7:31.
179. Stahl S.M., Buckley P.F. Negative symptoms of schizophrenia: a problem that will not go away. Acta Psychiatr. Scand. 2007, 115:4-11.
180. Stefansson H., Ophoff R.A., Steinberg S., Andreassen O.A., Cichon S., Rujescu D., Werge T., Pietiläinen O.P., Mors O., Mortensen P.B., Sigurdsson E., Gustafsson O., Nyegaard M., Tuulio-Henriksson A., Ingason A., Hansen T., Suvisaari J., Lonnqvist J., Paunio T., Børglum A.D., Hartmann A., Fink-Jensen A., Nordentoft M., Hougaard D., Norgaard-Pedersen B., Böttcher Y., Olesen J., Breuer R., Möller H.J., Giegling I., Rasmussen H.B., Timm S., Mattheisen M., Bitter I., Réthelyi J.M., Magnusdottir B.B., Sigmundsson T., Olason P., Masson G., Gulcher J.R., Haraldsson M., Fossdal R., Thorgeirsson T.E., Thorsteinsdottir U., Ruggeri M., Tosato S., Franke B., Strengman E., Kiemeney L.A., Genetic Risk and Outcome in Psychosis (GROUP), Melle I., Djurovic S., Abramova L., Kaleda V., Sanjuan J., de Frutos R., Bramon E., Vassos E., Fraser G., Ettinger U., Picchioni M., Walker N., Toulopoulou T., Need A.C., Ge D., Yoon J.L., Shianna K.V., Freimer N.B., Cantor R.M., Murray R., Kong A., Golimbet V., Carracedo A., Arango C., Costas J., Jönsson E.G., Terenius L., Agartz I., Petursson H., Nöthen M.M., Rietschel M., Matthews P.M., Muglia P., Peltonen L., St Clair D., Goldstein D.B., Stefansson K., Collier D.A. Common variants conferring risk of schizophrenia. Nature 2009, 460:744-747.
181. Steinberg S., de Jong S., Irish Schizophrenia Genomics Consortium, Andreassen O.A., Werge T., Børglum A.D., Mors O., Mortensen P.B., Gustafsson O., Costas J., Pietiläinen O.P., Demontis D., Papiol S., Huttenlocher J., Mattheisen M., Breuer R., Vassos E., Giegling I., Fraser G., Walker N., Tuulio-Henriksson A., Suvisaari J., Lönnqvist J., Paunio T., Agartz I., Melle I., Djurovic S., Strengman E., GROUP, Jürgens G., Glenthøj B., Terenius L., Hougaard D.M., Ørntoft T., Wiuf C., Didriksen M., Hollegaard M.V., Nordentoft M., van Winkel R., Kenis G., Abramova L., Kaleda V., Arrojo M., Sanjuán J., Arango C., Sperling S., Rossner M., Ribolsi M., Magni V., Siracusano A., Christiansen C., Kiemeney L.A., Veldink J., van den Berg L., Ingason A., Muglia P., Murray R., Nöthen M.M., Sigurdsson E., Petursson H., Thorsteinsdottir U., Kong A., Rubino I.A., De Hert M., Réthelyi J.M., Bitter I., Jönsson E.G., Golimbet V., Carracedo A., Ehrenreich H., Craddock N., Owen M.J., O'Donovan M.C., Wellcome Trust Case Control Consortium 2, Ruggeri M., Tosato S., Peltonen L., Ophoff R.A., Collier D.A., St Clair D., Rietschel M., Cichon S., Stefansson H., Rujescu D., Stefansson K. Common variants at VRK2 and TCF4 conferring risk of schizophrenia. Hum. Mol. Genet. 2011, 20:4076-4081.
182. Stone J.M., Morrison P.D., Pilowsky L.S. Glutamate and dopamine dysregulation in schizophrenia-a synthesis and selective review. J. Psychopharmacol. 2007, 21:440-452.
183. Strauss G.P., Gold J.M. A new perspective on anhedonia in schizophrenia. Am. J. Psychiatry 2012, 169:364-373.
184. Strauss GP., Frank MJ., Waltz JA., Kasanova Z., Herbener ES., Gold JM. Deficits in positive reinforcement learning and uncertainty-driven exploration are associated with distinct aspects of negative symptoms in schizophrenia. Biol. Psychiatry 2011, 69:424-431.
185. Strauss G.P., Hong L.E., Gold J.M., Buchanan R.W., McMahon R.P., Keller W.R., Fischer B.A., Catalano L.T., Culbreth A.J., Carpenter W.T., Kirkpatrick B. Factor structure of the brief negative symptom scale. Schizophr. Res. 2012, 142:96-98.
186. Strauss G.P., Horan W.P., Kirkpatrick B., Fischer B.A., Keller W.R., Miski P., Buchanan R.W., Green M.F., Carpenter W.T. Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome. J. Psychiatr. Res. 2013, 47:783-790.
187. Strekalova T., Couch Y., Kholod N., Boyks M., Malin D., Leprince P., Steinbusch H.M. Update in the methodology of the chronic stress paradigm: internal control matters. Behav. Brain Funct. 2011, 7:9.
188. Suzuki G., Harper K.M., Hiramoto T., Funke B., Lee M., Kang G., Buell M., Geyer M.A., Kucherlapati R., Morrow B., Mannisto P.T., Agatsuma S., Hiroi N. Over-expression of a human chromosome 22q11.2 segment including TXNRD2, COMT and ARVCF developmentally affects incentive learning and working memory in mice. Hum. Mol. Genet. 2009, 18:3914-3925.
189. Swartz M.S., Perkins D.O., Stroup T.S., Davis S.M., Capuano G., Rosenheck R.A., Reimherr F., McGee M.F., Keefe R.S., McEvoy J.P., Hsiao J.K., Lieberman J.A., CATIE Investigators Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am. J. Psychiatry 2007, 164:428-436.
190. Takao K., Kobayashi K., Hagihara H., Ohira K., Shoji H., Hattori S., Koshimizu H., Umemori J., Toyama K., Nakamura H.K., Kuroiwa M., Maeda J., Atsuzawa K., Esaki K., Yamaguchi S., Furuya S., Takagi T., Walton N.M., Hayashi N., Suzuki H., Higuchi M., Usuda N., Suhara T., Nishi A., Matsumoto M., Ishii S., Miyakawa T. Deficiency of Schnurri-2, an MHC enhancer binding protein, induces mild chronic inflammation in the brain and confers molecular, neuronal, and behavioral phenotypes related to schizophrenia. Neuropsychopharmacology 2013, 38:1409-1425.
191. Talbot K. The sandy (sdy) mouse: a dysbindin-1 mutant relevant to schizophrenia research. Prog. Brain Res. 2009, 179:87-94.
192. Tanaka K.F., Ahmari S.E., Leonardo E.D., Richardson-Jones J.W., Budreck E.C., Scheiffele P., Sugio S., Inamura N., Ikenaka K., Hen R. Flexible Accelerated STOP Tetracycline Operator-knockin (FAST): a versatile and efficient new gene modulating system. Biol. Psychiatry 2010, 67:770-773.
193. Tanda K., Nishi A., Matsuo N., Nakanishi K., Yamasaki N., Sugimoto T., Toyama K., Takao K., Miyakawa T. Abnormal social behavior, hyperactivity, impaired remote spatial memory, and increased D1-mediated dopaminergic signaling in neuronal nitric oxide synthase knockout mice. Mol. Brain 2009, 2:19.
194. Tandon R., Nasrallah H.A., Keshavan M.S. Schizophrenia, "just the facts" 4. Clinical features and conceptualization. Schizophr. Res. 2009, 110:1-23.
195. Tandon R., Nasrallah H.A., Keshavan M.S. Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future. Schizophr. Res. 2010, 122:1-23.
196. Tarabeux, J., Kebir, O., Gauthier, J., Hamdan, F.F., Xiong, L., Piton, A., Spiegelman, D., Henrion, É., Millet, B., S2D team, Fathalli, F., Joober, R., Rapoport, J.L., DeLisi, L.E., Fombonne, É., Mottron, L., Forget-Dubois, N., Boivin, M., Michaud, J.L., Drapeau, P., Lafrenière, R.G., Rouleau, G.A., Krebs, M.O., 2011. Rare mutations in N-methyl-d-aspartate glutamate receptors in autism spectrum disorders and schizophrenia. Transl. Psychiatry 2011 1:e55.
197. Terranova JP., Chabot C., Barnouin MC., Perrault G., Depoortere R., Griebel G., Scatton B. SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist, alleviates disturbances of novelty discrimination in a social context in rats, a putative model of selective attention deficit. Psychopharmacology 2005, 181:134-144.
198. Tattan T.M., Creed F.H. Negative symptoms of schizophrenia and compliance with medication. Schizophr. Bull. 2001, 27:149-155.
199. Thomson P.A., Malavasi E.L., Grunewald E., Soares D.C., Borkowska M., Millar J.K. DISC1 genetics, biology and psychiatric illness. Front. Biol. 2013, 8:1-31.
200. Tillerson J.L., Caudle W.M., Parent J.M., Gong C., Schallert T., Miller G.W. Olfactory discrimination deficits in mice lacking the dopamine transporter or the D2 dopamine receptor. Behav. Brain Res. 2006, 172:97-105.
201. Torres G., Meeder B.A., Hallas B.H., Gross K.W., Horowitz J.M. Preliminary evidence for reduced social interactions in Chakragati mutants modelling certain symptoms of schizophrenia. Brain Res. 2005, 1046:180-186.
202. Treadway M.T., Zald D.H. Reconsidering anhedonia in depression: lessons from translational neuroscience. Neurosci. Biobehav. Rev. 2011, 35:537-555.
203. Treutlein J., Mühleisen T.W., Frank J., Mattheisen M., Herms S., Ludwig K.U., Treutlein T., Schmael C., Strohmaier J., Bösshenz K.V., Breuer R., Paul T., Witt S.H., Schulze T.G., Schlösser R.G., Nenadic I., Sauer H., Becker T., Maier W., Cichon S., Nöthen M.M., Rietschel M. Dissection of phenotype reveals possible association between schizophrenia and Glutamate Receptor Delta 1 (GRID1) gene promoter. Schizophr. Res. 2009, 111:123-130.
204. Trezza V., Campolongo P., Vanderschuren L.J. Evaluating the rewarding nature of social interactions in laboratory animals. Dev. Cogn. Neurosci. 2011, 1:444-458.
205. Tsai G.E., Lin P.Y. Strategies to enhance N-methyl-d-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr. Pharm. Des. 2010, 16:522-537.
206. van Os J., Kenis G., Rutten B.P. The environment and schizophrenia. Nature 2010, 468:203-212.
207. Vorstman J.A., Anney R.J., Derks E.M., Gallagher L., Gill M., de Jonge M.V., van Engeland H., Kahn R.S., Ophoff R.A. Autism Genome Project, the International Schizophrenia Consortium. No evidence that common genetic risk variation is shared between schizophrenia and autism. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 2013, 162:55-60.
208. Waddington J.L., O'Tuathaigh C.M., Remington G.J. The pharmacology and neuroscience of antipsychotic drugs. Schizophrenia 2011, 485-514. Wiley-Blackwell, Oxford. Third Edition. D.R. Weinberger, P.J. Harrison (Eds.).
209. Waddington J.L., Hennessy R.J., O'Tuathaigh C.M.P., Owoeye O., Russell V. Schizophrenia and the lifetime trajectory of psychotic illness: developmental neuroscience and pathobiology, redux. The Origins of Schizophrenia 2012, 3-21. Columbia University Press, New York. A.S. Brown, P.H. Patterson (Eds.).
210. Wallen-Mackenzie A., Nordenankar K., Fejgin K., Lagerstrom M.C., Emilsson L., Fredriksson R., Wass C., Andersson D., Egecioglu E., Andersson M., Strandberg J., Lindhe O., Schioth H.B., Chergui K., Hanse E., Langstrom B., Fredriksson A., Svensson L., Roman E., Kullander K Restricted cortical and amygdaloid removal of vesicular glutamate transporter 2 in preadolescent mice impacts dopaminergic activity and neuronal circuitry of higher brain function. J. Neurosci. 2009, 29:2238-2251.
211. Ward R.D., Kellendonk C., Simpson E.H., Lipatova O., Drew M.R., Fairhurst S., Kandel E.R., Balsam P.D. Impaired timing precision produced by striatal D2 receptor overexpression is mediated by cognitive and motivational deficits. Behav. Neurosci. 2009, 123:720-730.
212. Ward R.D., Kellendonk C., Kandel E.R., Balsam P.D. Timing as a window on cognition in schizophrenia. Neuropharmacology 2012, 62:1175-1181.
213. Watanabe S. Distress of mice induces approach behavior but has an aversive property for conspecifics. Behav. Processes 2012, 90:167-173.
214. Wiedholz L.M., Owens W.A., Horton R.E., Feyder M., Karlsson R.M., Hefner K., Sprengel R., Celikel T., Daws L.C., Holmes A. Mice lacking the AMPA GluR1 receptor exhibit striatal hyperdopaminergia and "schizophrenia-related" behaviors. Mol. Psychiatry 2008, 13:631-640.
215. Williams L.M., Whitford T.J., Nagy M., Flynn G., Harris A.W., Silverstein S.M., Gordon E. Emotion-elicited gamma synchrony in patients with first-episode schizophrenia: a neural correlate of social cognition outcomes. J. Psychiatry Neurosci. 2009, 34:303-313.
216. Willner P., Muscat R., Papp M. An animal model of anhedonia. Clin. Neuropharmacol. 1992, 15:550A-551A.
217. Wirgenes K.V., Sønderby I.E., Haukvik U.K., Mattingsdal M., Tesli M., Athanasiu L., Sundet K., Røssberg J.I., Dale A.M., Brown A.A., Agartz I., Melle I., Djurovic S., Andreassen O.A. TCF4 sequence variants and mRNA levels are associated with neurodevelopmental characteristics in psychotic disorders. Transl. Psychiatry 2012, 2:e112.
218. Wöhr M., Silverman J.L., Scattoni M.L., Turner S.M., Harris M.J., Saxena R., Crawley J.N. Developmental delays and reduced pup ultrasonic vocalizations but normal sociability in mice lacking the postsynaptic cell adhesion protein neuroligin2. Behav. Brain Res. 2012, 251:50-64.
219. Wong P., Chang C.C., Marx C.E., Caron M.G., Wetsel W.C., Zhang X. Pregnenolone rescues schizophrenia-like behavior in dopamine transporter knockout mice. PLoS One 2012, 7:51455.
220. Won H., Lee H.R., Gee H.Y., Mah W., Kim J.I., Lee J., Ha S., Chung C., Jung E.S., Cho Y.S., Park S.G., Lee J.S., Lee K., Kim D., Bae Y.C., Kaang B.K., Lee M.G., Kim E. Autistic-like social behaviour in Shank2-mutant mice improved by restoring NMDA receptor function. Nature 2012, 486:261-265.
221. Yadav R., Gupta S.C., Hillman B.G., Bhatt J.M., Stairs D.J., Dravid S.M. Deletion of glutamate delta-1 receptor in mouse leads to aberrant emotional and social behaviors. PLoS One 2012, 7:32969.
222. Yadav R., Hillman B.G., Gupta S.C., Suryavanshi P., Bhatt J.M., Pavuluri R., Stairs D.J., Dravid S.M. Deletion of glutamate delta-1 receptor in mouse leads to enhanced working memory and deficit in fear conditioning. PLoS One 2013, 8:e60785.
223. Yizhar O., Fenno L.E., Prigge M., Schneider F., Davidson T.J., O'Shea D.J., Sohal V.S., Goshen I., Finkelstein J., Paz J.T., Stehfest K., Fudim R., Ramakrishnan C., Huguenard J.R., Hegemann P., Deisseroth K. Neocortical excitation/inhibition balance in information processing and social dysfunction. Nature 2011, 477:171-178.
224. Yue W.H., Wang H.F., Sun L.D., Tang F.L., Liu Z.H., Zhang H.X., Li W.Q., Zhang Y.L., Zhang Y., Ma C.C., Du B., Wang L.F., Ren Y.Q., Yang Y.F., Hu X.F., Wang Y., Deng W., Tan L.W., Tan Y.L., Chen Q., Xu G.M., Yang G.G., Zuo X.B., Yan H., Ruan Y.Y., Lu T.L., Han X., Ma X.H., Wang Y., Cai L.W., Jin C., Zhang H.Y., Yan J., Mi W.F., Yin X.Y., Ma W.B., Liu Q., Kang L., Sun W., Pan C.Y., Shuang M., Yang F.D., Wang C.Y., Yang J.L., Li K.Q., Ma X., Li L.J., Yu X., Li Q.Z., Huang X., Lv L.X., Li T., Zhao G.P., Huang W., Zhang X.J., Zhang D. Genome-wide association study identifies a susceptibility locus for schizophrenia in Han Chinese at 11p11.2. Nat. Genet. 2011, 43:1228-1231.